467 related articles for article (PubMed ID: 16968848)
21. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
22. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
23. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
[TBL] [Abstract][Full Text] [Related]
24. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
[TBL] [Abstract][Full Text] [Related]
25. Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study.
Okin PM; Devereux RB; Liu JE; Oikarinen L; Jern S; Kjeldsen SE; Julius S; Wachtell K; Nieminen MS; Dahlöf B
J Hum Hypertens; 2004 Jun; 18(6):403-9. PubMed ID: 15057252
[TBL] [Abstract][Full Text] [Related]
26. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
[TBL] [Abstract][Full Text] [Related]
27. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation.
Okin PM; Gerdts E; Wachtell K; Oikarinen L; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2010 Jul; 28(7):1534-40. PubMed ID: 20589977
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
29. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
[TBL] [Abstract][Full Text] [Related]
30. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Edelman JM; Devereux RB
Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
[TBL] [Abstract][Full Text] [Related]
31. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
[TBL] [Abstract][Full Text] [Related]
32. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.
Okin PM; Hille DA; Larstorp AC; Wachtell K; Kjeldsen SE; Dahlöf B; Devereux RB
Hypertension; 2015 Aug; 66(2):368-73. PubMed ID: 26056336
[TBL] [Abstract][Full Text] [Related]
33. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):243-51. PubMed ID: 23403268
[TBL] [Abstract][Full Text] [Related]
34. The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
Okin PM; Kjeldsen SE; Lindholm LH; Dahlöf B; Devereux RB
Blood Press; 2012 Jun; 21(3):146-52. PubMed ID: 22243363
[TBL] [Abstract][Full Text] [Related]
35. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
[TBL] [Abstract][Full Text] [Related]
36. Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Eur J Heart Fail; 2011 Apr; 13(4):384-91. PubMed ID: 21239405
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive therapy prevents new-onset atrial fibrillation in patients with isolated systolic hypertension: the LIFE study.
Larstorp ACK; Stokke IM; Kjeldsen SE; Hecht Olsen M; Okin PM; Devereux RB; Wachtell K
Blood Press; 2019 Oct; 28(5):317-326. PubMed ID: 31259628
[No Abstract] [Full Text] [Related]
38. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
Bang CN; Okin PM; Køber L; Wachtell K; Gottlieb AB; Devereux RB
J Hypertens; 2014 Mar; 32(3):667-72. PubMed ID: 24379001
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
40. Persistence of left ventricular hypertrophy is associated with increased cardiovascular morbidity and mortality in hypertensive patients with lower achieved systolic pressure during antihypertensive treatment.
Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
Blood Press; 2014 Apr; 23(2):71-80. PubMed ID: 23721506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
